Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Ruxolitinib Therapy


Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Ruxolitinib Therapy
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Davis KL et al. Real-world assessment of clinical outcomes in lower-risk myelofibrosis patients receiving treatment with ruxolitinib. Proc ASH 2014;Abstract 1857.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.